Roche’s big hope breast cancer drug fails in crucial first-line trial

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months

HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months

Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks